 |
INTRODUCTION |
Human host cell factor-1
(HCF-1)1 is a transcriptional
regulatory protein that was originally identified as an accessory
factor required for induction of herpes simplex virus immediate-early genes by the viral transactivator VP16 (1-5). Subsequently, findings demonstrated that HCF-1 is an essential cellular protein that is
required for cell proliferation (6). HCF-1 binds directly to VP16 and,
in conjunction with the cellular octamer-binding transcription factor
Oct-1 promotes the cooperative assembly and stability of a
multicomponent protein·DNA transcription complex termed the
VP16-induced complex (VIC) on regulatory elements present in the
promoter regions of the herpes simplex virus immediate-early genes
(reviewed in Refs. 1 and 7). Numerous studies of VP16 and its
association with Oct-1, HCF-1, and DNA have provided fundamental insights into mechanisms of transcriptional activation and how combinatorial networks of protein/protein and protein/DNA interactions underpin complexity, specificity, and diversity in transcriptional regulation (1, 7).
Human HCF-1 is a ubiquitously expressed and evolutionarily conserved
protein with a number of unusual properties and features (3, 5, 8, 9).
HCF-1 is synthesized as a 2035-amino acid long precursor protein that
is autocatalytically processed at centrally reiterated 26-amino acid
repeat elements (HCFPRO repeats) to generate a family of N-
and C-terminal polypeptides that remain tightly, but noncovalently,
associated with each other (10-13). VP16 associates with a discrete
380-residue N-terminal modular domain referred to as
HCFVIC (also called the kelch domain), which is composed of
six repeated copies of a kelch-like sequence proposed to form a
barrel-like six-bladed
-propeller (14). The HCFVIC
domain is necessary and sufficient to bind VP16, to stabilize VIC, and
to promote transactivation (14).
In addition to subserving a role in viral gene expression, HCF-1 is
essential for normal cell cycle progression (6). This finding arose
from studies of tsBN67 cells, a temperature-sensitive hamster cell line
that reversibly arrests at the G0/G1 decision point of the cell cycle at the nonpermissive temperature. The defect in
tsBN67 cells is due to a single proline-to-serine missense mutation
(P134S) at position 134 in HCF-1 (6). Interestingly, HCF-1(P134S) also
fails to bind to VP16 (14), foretelling the existence of cellular
factors that mimic VP16 in their interaction with HCF-1. The first such
HCF-1-interacting cellular factor identified was LZIP (also called
Luman) (15-17), a basic leucine zipper protein belonging to the cAMP-responsive element-binding protein/activating transcription factor family of transcription factors. Like VP16, LZIP
and a related protein called Zhangfei (18) target determinants in the
HCFVIC domain. More recently, the transcription factors GA-binding protein (19) and Sp1 (20), the nuclear hormone receptor
co-regulatory factor PGC-1 (21), and a protein phosphatase (22) have
been shown to associate with HCF-1.
The foregoing adds to growing evidence that HCF-1 is an essential,
multifunctional, co-regulatory protein that plays a global role in
coordinating viral and cellular gene regulation and cell proliferation.
However, the cellular role and mechanisms of action of HCF-1 and the
identity of its cellular gene targets are essentially unknown. Recent
findings show that HCF-1 is chromatin-associated, and it has been
postulated that HCF-1 is recruited to DNA through its association with
sequence-specific DNA-binding proteins, analogous to what occurs with
VP16 and Oct-1 (23). The HCFVIC domain is necessary and
sufficient for chromatin association, and the P134S mutation renders
this association temperature-sensitive, suggesting that this detachment
is responsible for the growth arrest phenotype in tsBN67 cells (23).
However, the minimal region capable of rescuing tsBN67 cells
encompasses residues 1-902, which include the HCFVIC
domain and a downstream region rich in basic amino acids (6, 14).
Moreover, the binding of the cellular proteins LZIP and Zhangfei to
HCF-1 is not required to rescue tsBN67 cells and to promote cell cycle
progression (23, 24). This indicates that other cellular factors
important for cell cycle control that target the N-terminal domain
and/or the basic region of HCF-1 may exist. The importance of the basic
region in cell proliferation is underscored by recent studies with the
HCF-1 family member HCF-2 and the related Caenorhabditis
elegans homolog (25, 26). HCF-1, HCF-2, and C. elegans
HCF share conserved N- and C-terminal domains; however, HCF-2 and
C. elegans HCF lack the basic region and the central
HCFPRO repeats. Although HCF-2 and C. elegans HCF are able to support VIC formation, these proteins are unable to
rescue the temperature-sensitive cell cycle defect in tsBN67 cells
(26). Coexpression of HCF-2 inhibits rescue by HCF-1, however,
suggesting that the two factors share a common interacting partner(s)
(25). The foregoing indicates that the basic region of HCF-1 provides
an additional function that is required, in conjunction with the
N-terminal proximal region, to promote cell cycle progression.
To shed light on the cellular and functional roles of HCF-1, we carried
out yeast two-hybrid interaction cloning with the HCF-1 basic region as
bait to identify putative cellular factors that target this region. We
show here that HCF-1 interacts physically and functionally with Miz-1,
a recently identified cell cycle regulatory factor that was originally
isolated by virtue of its ability to interact with the cellular
oncoprotein c-Myc (27-29). Miz-1 is an 803-amino acid long POZ
domain/zinc finger transcription factor that modulates transcription by
binding directly to initiator elements of target genes (27, 30, 31). In
contrast to the stimulation of cell cycle progression ascribed to
HCF-1, Miz-1 causes cell cycle arrest at G1 (27). This is
manifested in part by Miz-1-mediated activation of the gene encoding
the key cell cycle inhibitor p15INK4b, a potent inhibitor
of cyclin-dependent kinases (30). Accumulation of
p15INK4b at G1 results in cell cycle arrest due
to a reduction in cyclin D1-associated kinase activity. Recent studies
have shown that transcriptional activation of p15INK4b and
the subsequent cell cycle arrest are potentiated by the antimitogenic cytokine transforming growth factor-
and antagonized by the cell proliferation mediator c-Myc through opposing pathways that directly converge on Miz-1 (30, 33). Thus, c-Myc binds directly to Miz-1 on the
p15INK4b initiator element and represses Miz-1
transactivation by abrogating recruitment of the coactivator p300.
Conversely, transforming growth factor-
activates SMAD proteins,
which relieve c-Myc-mediated repression by causing the dissociation of
c-Myc from Miz-1 and which directly transactivate the
p15INK4b promoter in cooperation with Miz-1. Miz-1 is thus
at the nexus of reciprocal growth regulatory signaling pathways that
link p15INK4b to cell cycle control (32).
We demonstrate here that Miz-1/HCF-1 association is manifested through
the basic domain of HCF-1 and by two independent regions of Miz-1: the
N-terminal POZ domain and a C-terminal transactivation domain. We
further show that HCF-1 represses Miz-1-mediated transactivation of a
reporter gene linked to the p15INK4b promoter, likely as a
result of HCF-1 interfering with the recruitment of p300 to Miz-1.
Thus, HCF-1 functions in a manner analogous to c-Myc in modulating
Miz-1 function. Our findings point to a convergence between two
regulatory proteins that have opposing roles in cell proliferation and
may thus be relevant to the mechanisms by which HCF-1 promotes cell
cycle progression.
 |
EXPERIMENTAL PROCEDURES |
Plasmids--
Mammalian expression vectors pCGNHCF and pFLAG-C1,
encoding hemagglutinin/c-Myc and FLAG epitope-tagged derivatives
of full-length human HCF-1, respectively, have been described (3, 18)
and were provided by W. Herr and T. Kristie, respectively.
pCGNHCF-1FL(P134S) (where FL is full-length) was constructed by
isolating a SpeI/XhoI fragment from pCGNHCF and
inserting this fragment into pCGNHCF-1-(1-1011)(P134S), supplied by A. Wilson (25). A mammalian expression vector encoding V5 epitope-tagged
full-length Miz-1 was provided by R. Tjian (31). Mammalian expression
vectors for full-length Miz-1 (pPK7) and human c-Myc (pMNBabeIRESc-Myc)
were obtained from M. Eilers (27) and L. Penn (University of Toronto),
respectively. pGal4(5X)luc, a luciferase reporter vector
that contains five upstream copies of the Gal4-binding site, was
obtained from J. Hassell (McMaster University).
p15INK4bluc, a luciferase reporter gene that
contains sequences spanning
113 to +160 relative to the transcription
start site of the p15INK4b promoter, was provided by M. Eilers (30). The in vitro transcription vector pSPUTK was
obtained from D. Andrews (McMaster University). The yeast two-hybrid
bait plasmid pGBT9-HCF-1-(450-1439), which contains residues 450-1439
of HCF-1 linked to the Gal4 DNA-binding domain (DBD), was constructed
by cloning a PCR fragment corresponding to this region into the
two-hybrid vector pGBT9 (Clontech). Similarly, pGBT9-HCF-1-(1-380) expresses the HCFVIC subdomain.
Deletions of HCF-1 were constructed in pGBT9 by conventional or
PCR-based methods using appropriate primers. The Gal4 activation domain (AD)-VP16 fusion protein (residues 1-404 of VP16) was cloned into pGAD424 (Clontech). Mammalian Gal4-DBD-Miz-1
derivatives were derived by subcloning PCR-derived
XhoI/BamHI subfragments into the corresponding
sites of the Gal4 fusion protein expression vector pSG424 by standard
procedures. A mammalian expression plasmid for HCF-1-(750-902)
was generated by amplifying this fragment from pCGNHCF and cloning into
the XhoI site of pCMV/Myc/nuc (Invitrogen). This construct
expresses HCF-1-(750-902) tagged with a c-Myc epitope and containing a
nuclear localization signal at the C terminus. Various glutathione
S-transferase (GST)-HCF-1 and GST-Miz-1 derivatives, as
indicated in the figure legends, were constructed by cloning PCR
fragments into the EcoRI/SalI sites of pGEX4T1
(Amersham Biosciences). GST-VP16-(1-404) contains residues 1-404 of
VP16 cloned into pGEX2T. In vitro transcription/translation
vector for full-length Miz-1 was generated by cloning the Miz-1 open
reading frame into the NcoI and SalI sites of
pGEM5zf (Promega). In vitro expression vectors for Miz-1
derivatives expressing the POZ domain (residues 109-308) and residues
637-803 were generated by cloning PCR fragments into pSPUTK. In
vitro expression vectors for HCF-1-(612-902) and HCF-1-(1-902)
were constructed by cloning appropriate PCR fragments into pSPUTK and
pGEM5zf, respectively. The GST-p300-(1572-2371) plasmid was obtained
from R. Eckner, and the pcDNA-Myc vector used for in
vitro transcription/translation was provided by M. Eilers.
Site-directed mutagenesis of pGEM5zf-HCF-1-(1-902) to incorporate the
P134S mutation was performed using the QuikChange site-directed
mutagenesis kit (Stratagene) with the following mutagenic primers:
5'-AAAAACGGGCCCCCTTCGTGTCCTCGACTC-3' and
5'-GAGTCGAGGACACGAAGGGGGCCCGTTTTTG-3' (altered nucleotides
are underlined). The authenticity of all clones constructed above was
verified by DNA sequence analysis. Mammalian Gal4-VP16AAD, which
expresses the Gal4 DBD linked to the C-terminal acidic activation
domain of VP16 has been described (34).
Yeast Two-hybrid Screening--
Two-hybrid analysis was carried
out using the Clontech Matchmaker system
essentially as described (35, 36). Briefly, yeast strain HF7c
(MATa, ura3-52, his3-200,
ade2-101, lys2-801, trp1-901,
leu2-3,112, canr, gal4-542,
gal80-538, URA3::GAL1-lacZ)
was transformed with pGBT9-HCF-1-(450-1439) and a HeLa cell Matchmaker
cDNA library fused to the Gal4 AD (Clontech) by
the lithium acetate method (37). Independent transformants (2 × 106) were grown on His
, Leu
,
and Trp
plates supplemented with 20 mM
3-amino-1,2,4-triazole. Library plasmids from His+ colonies
were selectively recovered from yeast following transformation into
Escherichia coli HB101 (leuB
),
transformed along with pGBT9-HCF-1-(450-1439) or control Gal4-DBD plasmids into yeast strain Y190 and assayed for
-galactosidase activity using the
-galactosidase overlay assay (36). Colonies that
scored positive for
-galactosidase activity in the presence of the
HCF-1 bait plasmid, but not with control or irrelevant plasmids, were
sequenced. One clone containing a partial cDNA encoding amino acids
269-803 of Miz-1 was selected for further studies.
GST Pull-down Assays--
Protein binding assays with GST fusion
proteins and [35S]methionine-radiolabeled proteins
synthesized in vitro using a coupled rabbit reticulocyte
transcription/translation system (Promega) were carried out as
described previously (38). Briefly, E. coli BL21 cells
harboring expression vectors for GST-Miz-1, GST-HCF-1, or GST alone
were grown to an A600 nm of 0.6-0.8 and
induced with isopropyl-
-D-thiogalactopyranoside
(Gibco BRL) for 3 h. Bacteria were collected by
centrifugation and resuspended in buffer containing 0.5% Nonidet P-40,
1 mM EDTA, 20 mM Tris-Cl (pH 8.0), 100 mM NaCl, and one tablet of mini C protease inhibitor
(Roche Molecular Biochemicals)/25 ml of buffer, and cell extracts were prepared by sonication. 50 µl of a 50:50 slurry of
glutathione-Sepharose 4B was incubated with clarified cell extracts
containing GST or GST fusion protein for 1 h at 4 °C. Beads
were collected by centrifugation and washed twice with
phosphate-buffered saline, and beads containing equivalent amounts of
bound protein (as determined by Coomassie Blue staining of
SDS-polyacrylamide gels) were incubated with 10-20 µl of
reticulocyte lysate containing radiolabeled translated protein in
buffer A (150 mM KCl, 0.02 mg/ml bovine serum
albumin, 0.1% Triton X-100, 0.1% Nonidet P-40, 5 mM
MgCl2, and 20 mM Hepes (pH 7.9)) for 2-3 h at
4 °C. Beads were washed extensively with buffer A lacking bovine
serum albumin, and bound radiolabeled proteins were eluted from the
beads by boiling in SDS sample buffer and analyzed by SDS-PAGE.
Competition assays were carried out with unlabeled competitor protein
synthesized in vitro as detailed in the figure legends. The
total amount of rabbit reticulocyte lysate was kept constant by adding
unprogrammed lysate to the binding reactions as required.
Cell Culture, Transfections, and Luciferase Assays--
COS-1
cells were cultured at 37 °C in Dulbecco's modified Eagle's medium
supplemented with 10% fetal bovine serum, 1% L-glutamine, and 1% penicillin/streptomycin. Cells were seeded in six-well plates
at a concentration of 2-3 × 105 cells/well 1 day
prior to transfection to achieve 70-80% confluence. Transfections
were carried out using LipofectAMINE reagent (4-8 µl/well;
Invitrogen) as outlined by the manufacturer. Unless indicated otherwise
in the figure legends, transfections typically contained 0.5 µg of
luciferase reporter plasmid (pGal4(5X)luc or
p15INK4bluc) and 0.05-0.5 µg of various
effector plasmids (HCF-1, Miz-1, c-Myc, or derivatives thereof). Total
DNA and promoter dosage was kept constant with the appropriate amounts
of corresponding empty vectors. Luciferase activity was assayed in cell
lysates prepared 48 h post-transfection and normalized to protein concentration.
Co-immunoprecipitation Assay--
Transfections were carried out
as described above using expression plasmids (0.5 µg/well) for
V5-Miz-1FL and/or FLAG-HCF-1FL. Lysates were prepared 48 h
post-transfection using Nonidet P-40 lysis buffer (150 mM
NaCl, 50 mM Tris (pH 8.0), 1% Nonidet P-40, and 0.2 mM phenylmethylsulfonyl fluoride). 1 ml of clarified
supernatant, normalized for protein concentration, was precleared with
50 µl of protein G-Sepharose (Roche Molecular Biochemicals) and
incubated with 1 µg of anti-FLAG antibody (Upstate Biotechnology,
Inc.) and 50 µl of protein G-Sepharose for 2 h at 4 °C.
Immune complexes were collected, extensively washed, suspended in 50 µl of SDS-polyacrylamide gel sample buffer, and subjected to PAGE.
Proteins were transferred to HybondTM-C pure nitrocellulose
membrane (Amersham Biosciences) and probed using mouse anti-V5
monoclonal antibody (Invitrogen) as the primary antibody, followed by
horseradish peroxidase-coupled sheep anti-mouse polyclonal antibody
(Amersham Biosciences) as the secondary antibody. Proteins were
detected by enhanced chemiluminescence with a commercially available
kit (ECL, Amersham Biosciences) according to the manufacturer's instructions.
Immunoblotting--
COS-1 cells were transfected as described
above, except that 1 µg of the various Gal4-Miz-1 expression plasmids
was used. Preparation of cell extracts for immunoblotting using
HybondTM-C pure nitrocellulose membrane was carried out as
described (36, 38). Gal4 fusion proteins were detected by ECL as
described above using mouse anti-Gal4 DNA-binding domain monoclonal
antibody (Santa Cruz Biotechnology) as the primary antibody
and horseradish peroxidase-coupled sheep anti-mouse polyclonal antibody
as the secondary antibody.
 |
RESULTS |
HCF-1 Interacts with Miz-1 via Determinants in the Basic
Domain--
We carried out yeast two-hybrid screens to identify novel
HCF-1-interacting proteins that may provide insights into the cellular functions, targets, and mechanisms of action of HCF-1. Similar approaches by others (15, 16) have used the N-terminal domain (residues
1-450) of HCF-1 as bait because this region is known to be sufficient
for interaction with VP16 and for promoting VIC formation (14). We
focused our attention on a separate region of HCF-1 (residues
450-1439) that encompasses the basic domain (Fig.
1A) because this region has
been shown to be required, along with the HCFVIC domain, to
rescue the temperature-sensitive block to cell cycle progression in
tsBN67 cells (14). The rationale was that the basic region may target
novel HCF-1-interacting proteins that subserve a role in cell cycle
regulation and/or other functions of HCF-1 that are independent of the
HCFVIC region.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 1.
HCF-1 interacts with Miz-1.
A, schematic diagram of the structure and functional domains
of HCF-1. Regions that are targeted by VP16 and various cellular
factors are indicated. The asterisk indicates the position
of the P134S point mutation. Also illustrated is the region used as
bait in the two-hybrid screen. ZF, zhangfei;
GABP, GA-binding protein; NLS, nuclear
localization signal. B, two-hybrid analysis of Miz-1/HCF-1
interaction. Yeast strain Y190 cells harboring the indicated Gal4-DBD
and Gal4-AD fusions (numbering corresponds to the amino acids in the
respective proteins) were assayed for -galactosidase expression by
the X-gal
(5-bromo-4-chloro-3-indolyl- -D-galactopyranoside)
overlay assay method. The Gal4-AD-VP16 fusion plasmid contains residues
1-404 of VP16. Interaction is indicated by ++. C, HCF-1 and
Miz-1 interact in vivo in mammalian cells. COS-1 cells were
transfected with expression vectors for FLAG-HCF-1FL and V5-Miz-1FL or
V5-Miz-1FL alone as indicated. Cell lysates were immunoprecipitated
(IP) with anti-FLAG antibody and analyzed by Western
blotting with anti-V5 antibody to detect Miz-1. 10% Input
represents 10% of the lysate used in the immunoprecipitation reactions
with anti-FLAG antibody.
|
|
Yeast two-hybrid screens using a Gal4-DBD-HCF-1-(450-1439) fusion
protein as bait resulted in the identification of several novel
HCF-1-interacting proteins from a HeLa cell Gal4 AD cDNA library.
Among the clones identified were isolates containing partial cDNAs
encoding a zinc finger transcription factor called Miz-1, a recently
described protein that was originally isolated by virtue of its ability
to interact with the cellular oncoprotein c-Myc (27, 28). Miz-1 is an
803-amino acid long protein that contains 13 zinc fingers of the
C2H2 class and an N-terminal POZ domain (see
Fig. 3A). The longest Miz-1 cDNA clone that we isolated from the two-hybrid screen encoded residues 269-803 of Miz-1 and is
thus missing the N-terminal POZ domain. As shown in Fig. 1B, HCF-1 bound specifically to Miz-1, as
-galactosidase activity was
observed only in the presence of both Gal4-DBD-HCF-1 bait and
Gal4-AD-Miz-1 prey plasmids. Significantly, Miz-1 failed to interact
with HCF-1 residues 1-380 (Fig. 1B), a domain that is sufficient for interaction with VP16 and the cellular factors LZIP and
Zhangfei (14-17).
To determine whether Miz-1 and HCF-1 associate in vivo in
mammalian cells, we carried out co-immunoprecipitation experiments with
cells cotransfected with expression vectors for V5-tagged full-length
Miz-1 and FLAG-tagged full-length HCF-1. Cell extracts were
immunoprecipitated with anti-FLAG antibody and probed with anti-V5
antibody. As shown in Fig. 1C, full-length Miz-1 was present in immune complexes precipitated with anti-FLAG antibody from cells
that had been transfected with both FLAG-HCF-1FL and V5-Miz-1FL expression vectors, but not from control cells that were transfected with V5-Miz-1FL alone. Thus, Miz-1 and HCF-1 form a stable complex in vivo in mammalian cells.
To map more precisely the region in HCF-1 that is targeted by Miz-1, we
constructed a series of deletions within Gal4-DBD-HCF-1-(450-1439) and
tested these for interaction by two-hybrid analysis with
Gal4-AD-Miz-1-(269-803). As shown in Fig.
2, a fusion protein containing HCF-1
residues 750-836 was sufficient to bind to Miz-1. Residues between 836 and 1439, which include the HCFPRO repeats, were not
necessary for interaction. However, the strongest binding, as reflected by
-galactosidase activity, was observed with HCF-1-(750-902), suggesting that residues between 836 and 902 may contribute to more
robust binding and/or stability of the Miz-1·HCF-1 complex in
vivo. A fragment spanning residues 836-902 was, however,
insufficient to bind with Miz-1. Miz-1 bound directly to HCF-1, as
determined by reciprocal GST pull-down assays with radiolabeled
proteins synthesized in vitro (Fig.
3B). As shown in Fig.
3B, radiolabeled full-length Miz-1 bound to
GST-HCF-1-(750-902), but not to GST alone. Thus, Miz-1 targets part of
the basic region of HCF-1 that is required for cell cycle progression
(14), with amino acid residues between 750 and 836 being of particular
importance for interaction.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 2.
Miz-1 targets the basic region of HCF-1.
N- and C-terminal deletions of HCF-1 between residues 450 and 1439, as
indicated, were cloned into the Gal4-DBD plasmid and tested for
interaction with Miz-1 (residues 269-803) by two-hybrid analysis in
yeast. Specific -galactosidase activity was determined by the liquid
quantitative assay. The values shown represent the mean
-galactosidase ( -GAL) activity ± S.D. from three
independent transformants assayed in duplicate.
|
|

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 3.
HCF-1 interacts directly with Miz-1 in
vitro and targets two separate domains, the POZ domain and
the C-terminal region. A, schematic representation of
Miz-1 indicating the N-terminal POZ domain and the positions of 13 zinc
finger motifs (represented by ovals). Subregions of Miz-1
involved in protein/protein interactions with c-Myc, p300, and SMAD
proteins are indicated. Also illustrated is the region of Miz-1
(residues 269-803) encoded in the cDNA retrieved in the two-hybrid
screen. B, in vitro GST pull-down assay.
[35S]Methionine-labeled Miz-1 or HCF-1 derivatives
synthesized in vitro were incubated with GST alone or with
various GST fusion proteins as indicated, and bound material was
analyzed by SDS-PAGE. The 1/10 LOAD lanes represent 10% of
the [35S]methionine-labeled protein added to the
respective binding assays. C, schematic representation of
the Miz-1 deletion constructs used above and summary of the in
vitro HCF-1 interaction results. +, specific interaction; , no
interaction.
|
|
HCF-1 Targets Two Separate Domains of Miz-1--
As summarized in
Fig. 3A, Miz-1 interacts with a number of cellular
regulatory proteins, including c-Myc (27), p300 (30), and SMAD proteins
(33). c-Myc binds via two separate regions in Miz-1, residues 269-308
and 637-718. Determinants contained within or overlapping these
separate regions are also important for interaction with p300. SMAD
proteins interact with Miz-1 via a region that encompasses the four
N-terminal proximal zinc fingers (33). To identify the region(s) of
Miz-1 that are required for interaction with HCF-1 and potential
relationships to other protein/protein interaction interfaces present
in Miz-1, we generated a series of deletions of Miz-1 and tested
binding to HCF-1 in vitro in GST pull-down assays. As shown
in Fig. 3B, a Miz-1 subfragment spanning residues 637-803
bound very efficiently and specifically to GST-HCF-1-(750-902). In
reciprocal binding experiments, radiolabeled HCF-1-(612-902) bound to
GST-Miz-1-(637-803). The C-terminal region of Miz-1 that promotes
interaction with c-Myc and p300 has been mapped to residues 637-718
(27) and 683-715 (30), respectively. As shown in Fig. 3B,
radiolabeled HCF-1-(612-902) was unable to bind to overlapping
subfragments of Miz-1 corresponding to residues 637-738 and 719-803.
c-Myc and p300 also targeted N-terminal residues 269-308 and 190-294
of Miz-1, respectively. Miz-1-(109-308) was, however, unable to bind
to HCF-1 (Fig. 3B). These results suggest that
Miz-1/HCF-1 interaction is mediated by multiple determinants or an
extended region within residues 637-803 of Miz-1 and that HCF-1
targets determinants in Miz-1 that overlap with, but are distinguishable from, those required for interaction with c-Myc, p300,
and SMAD proteins.
The Miz-1 fragment isolated in the two-hybrid screen was missing
N-terminal residues 1-269, which include the POZ domain (residues 1-108). This indicates that the POZ domain is not required for interaction with Miz-1, at least in the presence of the C-terminal interacting domain. However, because POZ domains have been shown to
provide protein interaction interfaces (39-41), we tested whether this
region may bind independently to HCF-1. As shown in Fig. 3B,
reciprocal GST binding experiments with Miz-1-(1-108) demonstrated that the POZ domain itself was capable of interacting with HCF-1.
Thus, as summarized in Fig. 3C, Miz-1 contains at least two
modular subdomains that can independently bind to HCF-1. These regions
are distinct from those that mediate Miz-1 interaction with its other
known interacting partners. The foregoing does not preclude the
possibility that subregions of Miz-1 located between residues 108 and
637, which include the zinc finger cluster, are also important for or
influence interaction with HCF-1.
HCF-1 Targets a Transactivation Function in Miz-1--
Most of the
HCF-1-interacting factors identified to date, including Miz-1 described
herein, are themselves transcription factors, underscoring the growing
evidence that HCF-1 serves as a global transcriptional co-regulatory
factor. Recent findings have shown that, in some cases, HCF-1 is
recruited directly to the transcriptional activation domains of its
interacting partners, including those present in LZIP (42) and
GA-binding protein (19), suggesting that one role of HCF-1 may be to
directly modulate the activation potential of its interacting partners.
Because a Miz-1 transcriptional activation domain had not been
identified at the time, we sought to determine whether the HCF-1-binding interface at the C terminus of Miz-1 could serve as a
transactivation domain when tethered to DNA. For this purpose, we
tested a series of Gal4-Miz-1 fusion proteins by transient transfection
assays in mammalian cells using a luciferase reporter gene driven by a
promoter containing multiple upstream Gal4-binding sites. As shown in
Fig. 4A, full-length Miz-1
(Gal4-Miz-1FL), as well as a derivative lacking the N-terminal POZ
domain (Gal4-Miz-1
POZ), resulted in 13- and 31-fold induction of
reporter gene activity, respectively, relative to the activity obtained
with the Gal4 DBD alone. Thus, full-length Miz-1, as well as the
POZ
derivative, activates transcription when tethered directly to DNA.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 4.
The C-terminal HCF-1 interaction interface in
Miz-1 functions as an autonomous transactivation domain.
A, COS-1 cells were transfected with a Gal4-responsive
luciferase reporter plasmid along with expression vectors for various
Gal4-Miz-1 fusion derivatives as indicated, and luciferase activity was
measured. Values shown represent -fold activation relative to Gal4-DBD
empty vector control and represent the mean activity ± S.D. from
three independent transfections carried out in duplicate. B,
the expression levels of Gal4-DBD-Miz-1 fusion proteins were
determined. COS-1 cells were transfected with 1.0 µg of the indicated
Gal4-Miz-1 expression plasmid, and extracts were analyzed by Western
blot analysis with mouse anti-Gal4 DBD monoclonal antibody.
|
|
To determine whether the transactivation function maps to regions
required for interaction with HCF-1, we tested the activity of a Gal4
fusion with residues 637-803 of Miz-1. As shown in Fig. 4A,
Gal4-Miz-1-(637-803) potently activated transcription, resulting in a
253-fold activation of reporter gene expression relative to the Gal4
DBD alone. Interestingly, transactivation by this derivative was
significantly higher than that observed with the full-length protein or
the
POZ derivative, a difference that could not be attributed to
differences in expression levels of the respective proteins as
determined by Western blot analysis (Fig. 4B, lanes
1, 2, and 4, respectively). This suggests
that the more robust activation is an inherent property of this
isolated domain and that the full activation potential of this region
may be masked in the context of the intact protein.
Overlapping subfragments spanning residues 637-718 and 701-803 were
marginally active (4-5-fold induction over the control), whereas a
fragment containing residues 701-738 was inactive. These subfragments
were also unable to bind to HCF-1. As a control, we also tested
residues 176-284, a region that encompasses binding determinants for
c-Myc (see below) and that has been predicted to harbor an activation
function because of its high content of acidic amino acids (28). This
region was, however, unable to stimulate expression of the reporter gene.
Thus, the C-terminal HCF-1-interacting domain of Miz-1 harbors an
autonomous activation function. The potency of this region in
transactivation correlates with its ability to interact with HCF-1.
These findings add to the growing evidence that HCF-1 targets activation domains in its interacting partners.
HCF-1 Represses Gal4-Miz-1-mediated Transcriptional
Activation--
To begin to probe the functional consequences of
Miz-1/HCF-1 interaction, we carried out transient transfection assays
with various Gal4-Miz-1 fusion proteins in the presence or absence of
an expression vector for HCF-1 to determine whether HCF-1 modulates transactivation by Miz-1. As shown in Fig.
5A, cotransfection of
full-length HCF-1 led to a dose-dependent repression of
transactivation mediated by Gal4-Miz-1FL (Fig. 5A).
Similarly, HCF-1 inhibited transactivation by a Miz-1 derivative
lacking the POZ domain or a derivative containing only the C-terminal
transactivation domain (residues 637-803). In each case,
cotransfection of an HCF-1 expression vector led to ~70-80%
inhibition of activity at the highest concentrations of HCF-1 used. The
repressive effect was specific to Gal4-Miz-1 derivatives because
similar levels of HCF-1 had no effect on transactivation mediated by
Gal4-VP16AAD, a Gal4 derivative linked to the potent acidic
transactivation domain of VP16. Thus, the repression observed in Miz-1
transactivation is not due to a generalized titration of co-regulatory
factors by HCF-1. The observation that HCF-1 repressed Gal4-Miz-1FL and
Gal4-Miz-1
POZ to a similar degree suggests that inhibition by HCF-1
is independent of the POZ domain.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 5.
HCF-1 antagonizes transactivation by
Gal4-Miz-1. A, COS-1 cells were cotransfected with 0.5 µg of pGal4(5X)luc reporter plasmid and the indicated
Gal4-Miz-1 fusion expression vector (50 ng) or Gal4-VP16AAD (50 ng) in
the absence or presence of increasing amounts of an expression vector
for full-length HCF-1 as indicated. Extracts were prepared 40-48 h
later and assayed for luciferase activity. Values shown represent the
mean ± S.D. from three independent transfections carried out in
duplicate and are normalized to the value obtained from the respective
Gal4 fusion effector plasmid alone, which was taken as 100% for each
case. B, the minimal Miz-1-binding domain of HCF-1 was
sufficient to inhibit transactivation by Gal4-Miz-1. Transfections and
measurement of luciferase activity were carried out in an identical
manner as described for A, except that the expression vector
for HCF-1-(750-902) was used in place of full-length HCF-1.
|
|
We next tested whether the minimal Miz-1-binding domain in HCF-1
(HCF-1-(750-902)) can also affect Gal4-Miz-1-mediated transactivation. As illustrated in Fig. 5B, HCF-1-(750-902) behaved in a
manner analogous to full-length HCF-1, inhibiting the transactivation potential of all three Gal4-Miz-1 fusion proteins, but not that of
Gal4-VP16AAD. Thus, binding of this subfragment of HCF-1 directly to
the Miz-1 transactivation domain is sufficient to inhibit the activity
of Miz-1.
HCF-1 Represses Miz-1 Activation of the p15INK4b
Promoter--
Having shown a repressive effect of HCF-1 on the
transcriptional activity of Gal4-Miz-1 fusion proteins, we sought to
determine whether a similar effect could be observed with native Miz-1
in the context of a natural Miz-1 target gene. Miz-1 has recently been
shown to stimulate transcription of the cyclin-dependent kinase inhibitor p15INK4b through direct binding to the
initiator element in this promoter (30). To determine whether HCF-1
modulates Miz-1-mediated activation of p15INK4b expression,
we performed cotransfection assays with a luciferase reporter gene
linked to the p15INK4b promoter. As shown in Fig.
6, transfection of an expression vector for full-length Miz-1 led to a 7-fold induction of p15INK4b
reporter gene activity, consistent with recent findings reported by
others (30). In contrast, HCF-1 expression had no effect on reporter
gene activity. However, coexpression of HCF-1 with Miz-1 inhibited
Miz-1 mediated transactivation by ~70%.

View larger version (9K):
[in this window]
[in a new window]
|
Fig. 6.
HCF-1 represses Miz-1 activation of the
p15INK4b promoter. COS-1 cells were cotransfected with
a p15INK4bluc reporter along with expression
plasmids for full-length Miz-1, HCF-1, and/or c-Myc as indicated.
Values represent the mean activity ± S.D. from three independent
transfections done in duplicate and are normalized to the activity
obtained from the reporter plasmid alone, which was taken as 1.
|
|
Miz-1 activation of p15INK4b expression is also inhibited
by interaction with c-Myc (30). Consistent with this, transfection of a
c-Myc expression vector, although having no effect on its own,
repressed Miz-1-dependent activation of the reporter gene (Fig. 6). The extent of repression by c-Myc was comparable to that
observed with HCF-1. Interestingly, coexpression of both HCF-1 and
c-Myc led to an additive effect on inhibition of Miz-1 activity,
reducing activity to the basal levels observed with the reporter gene
alone. Thus, HCF-1, like c-Myc, antagonizes Miz-1-dependent activation of the native
p15INK4b promoter.
HCF-1 Interferes with Recruitment of p300 to Miz-1--
c-Myc has
been shown to inhibit transactivation by Miz-1 by interfering with
recruitment of the p300 coactivator (30). Because HCF-1 targets a
region of Miz-1 that is also involved in p300 association, we
speculated that HCF-1 might also function in this manner. To determine
whether this is the case, we carried out a mammalian two-hybrid assay
using Gal4-Miz-1FL and chimeric p300-VP16. As shown in Fig.
7A, transfection of cells with
the p300-VP16 expression vector on its own had no effect on reporter
gene activity. However, cotransfection expression vectors encoding
p300-VP16 and Gal4-Miz-1 led to a 2-fold increase in reporter gene
activity compared with cells transfected with Gal4-Miz-1 alone, similar to what has been previously observed (30). Inclusion of an expression vector encoding full-length HCF-1 abrogated the stimulatory effect of
p300-VP16 and further repressed Gal4-Miz-1FL transactivation potential.
To determine whether this is the result of HCF-1 interfering with the
recruitment of p300 to Miz-1, we used the GST pull-down competition
assay with a C-terminal fragment of p300 (residues 1572-237) that has
been shown to interact with Miz-1 (30) fused to GST along with
radiolabeled full-length Miz-1 and unlabeled competitor proteins
synthesized in vitro. As shown in Fig. 7B, full-length Miz-1 bound to GST-p300-(1572-2371) as expected. Inclusion of equivalent amounts of unlabeled HCF-1-(1-902), c-Myc, or Miz-1 (as
a positive control) reduced binding of radiolabeled Miz-1 by 60-70%
(HCF-1 did not bind to GST-p300; data not shown). In contrast,
inclusion of unlabeled luciferase (negative control) had no effect on
binding. Thus, HCF-1 competes with p300 for interaction with Miz-1.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 7.
HCF-1 inhibits p300 recruitment by
Miz-1. A, COS-1 cells were transfected with a
pGal4(5X)luc reporter gene in the presence of expression
vectors for Gal4-Miz-1FL (50 ng), full-length p300-VP16 (0.25 µg),
and/or full-length HCF-1 (0.25 µg) as indicated. Extracts were
prepared 40-48 h later and assayed for luciferase activity. Values
shown represent the means ± S.D. from two independent
transfections carried out in duplicate. B, HCF-1 interfered
with p300 binding to Miz-1. [35S]Methionine-labeled
full-length Miz-1 synthesized in vitro was incubated with
GST or GST-p300-(1572-2371) as indicated in the presence or absence of
various unlabeled competitor proteins synthesized in vitro.
Unlabeled competitor proteins included HCF-1-(1-902), full-length
c-Myc, full-length Miz-1, and luciferase. Bound material was analyzed
by SDS-PAGE. 5% Load represents 5% of the
[35S]methionine-labeled protein added to the binding
assays. Numbers shown at the bottom represent relative band
intensities as determined by PhosphorImager analysis and are shown
normalized to the reaction lacking unlabeled competitor protein, which
was set to 100.
|
|
The Causative Mutation in HCF-1 That Leads to Cell Cycle Arrest in
tsBN67 Cells Does Not Affect Binding to Miz-1--
A subfragment of
HCF-1 spanning residues 1-902, including the basic region that is
targeted by Miz-1, is necessary and sufficient to rescue the
temperature-sensitive cell cycle defect in tsBN67 cells (14). The
causative mutation (P134S) in HCF-1 also abrogates interaction with
cellular proteins such as LZIP (15, 17); however, this is incidental to
the ability of HCF-1 to promote cell cycle progression (24). As we have
shown, the N-terminal domain of HCF-1 (residues 1-380) is not
necessary for Miz-1 interaction in vitro or in
vivo. Nevertheless, the possibility remains that, in the context
of the native protein or larger subfragments of HCF-1, the P134S point
mutation may induce long-range perturbations that could modulate Miz-1
binding and/or function. To test this directly, we used GST pull-down
assays with GST-Miz-1-(637-803) and in vitro synthesized,
radiolabeled, wild-type HCF-1-(1-902) or the corresponding HCF-1
fragment harboring the P134S point mutation. As expected, radiolabeled
HCF-1-(1-902) bound to GST-Miz-1-(637-803), but not to GST alone
(Fig. 8A).
HCF-1-(1-902)(P134S) bound to GST-Miz-1-(637-803) as efficiently as
did wild-type HCF-1. As a positive control, we tested binding to
GST-VP16-(1-404), a GST fusion protein linked to residues 1-404 of
VP16 that contains determinants necessary for interaction with HCF-1
(34). As expected, HCF-1-(1-902), but not HCF-1-(1-902)(P134S), bound
to GST-VP16-(1-404).

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 8.
The P134S mutation in HCF-1 does not inhibit
binding to or transactivation by Miz-1. A, in
vitro synthesized, [35S]methionine-labeled
HCF-1-(1-902) or HCF-1-(1-902)(P134S) was incubated with GST,
GST-Miz-1-(637-803), or GST-VP16-(1-404) as indicated, and bound
material was analyzed by SDS-PAGE. 1/10 load represents 10%
of the [35S]methionine-labeled protein used in the
respective binding assays. B, COS-1 cells were cotransfected
with a Gal4-responsive luciferase reporter plasmid and the indicated
Gal4-Miz-1 fusion expression vector or Gal4-VP16AAD in the absence or
presence of increasing amounts of an expression vector for full-length
(wild-type (WT)) HCF-1 or HCF-1(P134S) as indicated and
assayed for luciferase activity as described in the legend to Fig.
5A.
|
|
To determine whether the P134S mutation affects the ability of HCF-1 to
attenuate Miz-1-mediated transactivation, we carried out transient
transfection experiments as described for Fig. 5. As shown in Fig.
8B, full-length HCF-1 harboring the P134S mutation retained
the ability to inhibit transactivation by Miz-1. Thus, under
these experimental conditions, the causative point mutation in HCF-1
that is responsible for the temperature-sensitive cell cycle defect in
tsBN67 cells does not interfere with association with Miz-1 or inhibit
transactivation by Miz-1.
 |
DISCUSSION |
HCF-1 is a complex, multifunctional protein that is essential for
normal cell cycle progression through the G0/G1
transition (6); however, its cellular roles and mechanisms of action
remain poorly understood. Our findings that HCF-1 physically and
functionally interacts with Miz-1, a cell cycle regulator that causes
cell cycle arrest at G1 (27, 30), and antagonizes
Miz-1-dependent activation of the gene encoding a key cell
cycle regulatory protein provide a provocative new dimension to the
activities of these two proteins that may be of consequence to their
respective roles in transcription and their reciprocal effects on cell
cycle progression.
Miz-1 targets determinants present in the basic region of HCF-1, a
domain that, in conjunction with the N-terminal region, is able to
rescue the cell cycle defect in tsBN67 cells (14). Whether Miz-1 is an
important effector in this process remains to be determined. Herr and
co-workers (14) demonstrated that the minimal fragment of HCF-1 capable
of rescuing the cell cycle defect in tsBN67 cells is residues 1-902
and that further C-terminal deletion of this fragment to position 836 abrogates rescue. The minimal Miz-1-binding interface mapped to
residues 750-836, and although residues between 836 and 902 enhance
binding with Miz-1, they are neither necessary nor sufficient for
interaction. Moreover, the causative mutation (P134S) in HCF-1 leading
to cell cycle arrest does not affect interaction with or
transactivation by Miz-1. The foregoing implies that Miz-1 may not be
necessary for HCF-1-mediated cell cycle control and that the phenotypic
basis of the P134S mutation may be related to as yet unidentified
proteins that target the N-terminal and/or basic regions. However, this does not necessarily negate a role for Miz-1 because cell cycle control
by HCF-1 is likely a highly complex process that involves the
cooperative interplay with many effector targets that recognize both
the N-terminal HCFVIC domain and the basic region. Recent studies have shown that the basic region of HCF-1 is targeted by
several other transcription factors, including GA-binding protein (19)
and Sp1 (20). More recently, we have identified a novel zinc finger
transcription factor that, like Miz-1, binds to residues 750-902 of
HCF-1.2 Thus, the basic
region of HCF-1 is targeted by at least four distinct transcription
factors. It will be of interest to unravel the combinatorial interplay
of these factors with HCF-1 and their potential relationships to the
function of HCF-1 in cell cycle regulation and/or transcriptional control.
HCF-1 targets two independent regions of Miz-1: the N-terminal POZ
domain and the C-terminal region spanning residues 637-803. The latter
region also harbors overlapping but distinguishable determinants for
interaction with c-Myc and the coactivator p300, suggesting the
possibility of functional interplay among these factors in their
interactions with Miz-1 (27, 30). Interestingly, region 637-803
functions as a potent autonomous transactivation domain, and
preliminary analysis indicates that the determinants required for
binding to HCF-1 and for transactivation are overlapping and/or
intimately linked. Thus, as has been shown to be the case with several
of its other interacting partners (19, 42), HCF-1 targets a
transactivation function in Miz-1. This finding underscores a potential
general functional property of HCF-1 whereby it modulates the activity
of its partner proteins by directly interacting with their respective
transactivation domains (see below). Interestingly, transcriptional
activation mediated by the isolated C-terminal domain was significantly
more robust vis-à-vis full-length Miz-1 or the
Miz-1
POZ derivative, suggesting that, in the context of the
full-length protein, other regions of Miz-1 lying between residues 109 and 637 may serve to dampen the activation potential of the C-terminal
transactivation domain. The full transcriptional activation potential
of Miz-1 may thus be triggered only at times when it has been relieved
of this attenuation.
Overexpression of Miz-1 results in G1 arrest via a process
mediated in part by induction of the gene for the
cyclin-dependent kinase inhibitor p15INK4b at
G1 (30), which leads in turn to a reduction in cyclin
D1-associated kinase activity. c-Myc binds directly to Miz-1 and
inhibits Miz-1 activation of p15INK4b expression,
consequently relieving cell cycle arrest and allowing progression
through the cell cycle. Conversely, p15INK4b expression is
stimulated by transforming growth factor-
, which activates SMAD
proteins, which prevent recruitment of c-Myc to Miz-1 and which
directly cooperate with Miz-1 in transactivating the
p15INK4b promoter (33). Thus, growth inhibition pathways
stimulated by transforming growth factor-
and growth stimulation
pathways induced by c-Myc converge through Miz-1 in the regulation of
p15INK4b gene transcription (32).
Functional analysis indicated that HCF-1 repressed transactivation by
Miz-1 both on the natural p15INK4b promoter and on
artificial Gal4-responsive promoters in a manner that was associated
with recruitment of p300 to Miz-1. This may point to a potential
mechanism by which HCF-1 may stimulate cell cycle progression. Thus, as
observed with c-Myc, inhibition of Miz-1 activation of
p15INK4b by HCF-1 may be expected to result in increased
activity of cyclin D1/CDK4 and thus progression through the
G1/S restriction point. Interestingly, repression of
p15INK4b expression was potentiated in the presence of both
HCF-1 and c-Myc, perhaps reflecting an aggregate response due to the
fact that both c-Myc and HCF-1 inhibit recruitment of p300 to
Miz-1.
Interference with p300 recruitment is one of several possible
mechanisms by which HCF-1 inhibits Miz-1 activity because HCF-1 also
independently associates with the Miz-1 POZ domain. POZ domains are
conserved protein/protein interaction motifs and, when found as part of
transcription factors, usually function as repressive domains, in part
through recruitment of corepressors such as N-CoR (nuclear
receptor corepressor) and SMRT (silencing
mediator for retinoid and thyroid
hormone receptors) (43, 44). The Miz-1 POZ domain is thought to be in a
latent repressive state, and it has been postulated that c-Myc serves
to convert the Miz-1 POZ domain into an active repressive domain (27).
Our findings demonstrate that HCF-1, as well as the minimal
Miz-1-interacting subregion (residues 750-902), inhibits
transactivation of both Gal4-Miz-1FL and Gal4-Miz-1
POZ fusion
proteins to a similar degree, suggesting that the POZ domain is not
involved in HCF-1-mediated repression. The relevance of HCF-1
interaction with the isolated Miz-1 POZ domain is unclear at present;
however, it may be related to results of a recent report showing that
Miz-1 is present in the cytoplasm in association with microtubules
(31). In the presence of drugs that induce expression of the low
density lipoprotein receptor, Miz-1 translocates to the nucleus, where
it binds to and activates transcription of the low density lipoprotein
receptor gene. Translocation under these circumstances requires the
integrity of the POZ domain, suggesting that the POZ domain may be
required for nuclear import of Miz-1 under certain conditions. HCF-1
has been shown to serve as a nuclear import factor for VP16 (45) and
thus could potentially play a similar role with Miz-1. Native HCF-1 is
found almost exclusively in the nucleus; however, discrete N-terminal
subfragments of HCF-1 have been shown to accumulate in the cytoplasm at
G0 (46). It is interesting to speculate that these
subfragments may modulate nuclear translocation of Miz-1, thereby
potentiating the repressive effects on Miz-1 activity.
In summary, we have identified Miz-1 as a novel interacting partner for
HCF-1 and illustrate an intriguing new pathway of regulation that
potentially links the opposing effects of these two proteins on cell
cycle control. Our findings also represent the first example of HCF-1
inhibiting transactivation of an associated transcription factor.
Recently, a novel HCF-1-related protein called HCF-like protein-1 has
been identified and shown to inhibit transactivation by LZIP (47).
Thus, HCF-1 and its family members may function as both coactivators
and corepressors of transcription. We believe that this dual nature can
serve HCF-1 well in cell cycle control because HCF-1 could function as
a coactivator of genes that are required for cell cycle progression
while also functioning as a corepressor of genes (such as
p15INK4b) that serve to inhibit cell cycle progression.
Further studies to elucidate the physiological importance of
Miz-1/HCF-1 interaction and functional interplay with other factors
involved in cell cycle control and gene regulation will be of interest.